Antiglucocorticoid drugs in the treatment of depression
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
A confluence of evidence indicates that prolonged elevation in gluco-corticoid level may result in disturbances of mood and cognition. In Cushing's syndrome, hypersecretion of cortisol is associated with a high incidence of depression, impairment in memory and hippocampal atrophy. Pharmacological usage of glucocorticoids is similarly productive of mood change and memory deficit. In patients with endogenous depression, hypercortisolaemia is associated with cognitive dysfunction and possibly a decrease in hippocampal volume. In each of these conditions, reduction of glucocorticoid level, either through discontinuation of steroid treatment or through usage of agents that block glucocorticoid synthesis, ameliorates the adverse behavioural effects. Traditional antidepressant agents may, in addition, stabilise mood through actions on the hypothalamic-pituitary adrenocortical (HPA) system. Although clinical usage of the currently available antiglucocorticoid drugs is limited by significant adverse side effect profiles, development of drugs specifically targeting the glucocorticoid receptor may lead to innovative strategies in the treatment of mood disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brain corticosteroid receptor balance in health and disease
de Kloet, E. R., Vreugdenhil, E., Oitzl, M. S., & Joëls, M. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.3.0331 · Cited by 2,614
Brain corticosteroid receptor balance in health and disease
de Kloet, E. R. (1998) · Endocrine Reviews · doi:10.1210/er.19.3.269 · Cited by 2,614
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129
Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging
Seeman, T. E., McEwen, B. S., Rowe, J. W., & Singer, B. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081072698 · Cited by 1,385 · cited 1×
“Such a nosology has proven useful in understanding the cost to the organism of constant and recurrent attempts to elicit a stress response, or ‘allostatic load’ [20].”
BackgroundGlucocorticoid receptors in major depression: relevance to pathophysiology and treatment
Pariante, C. M., & Miller, A. H. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01088-x · Cited by 1,147 · cited 2×
“At this point, the data does not indicate whether HPA axis normalisation and clinical recovery are dependent on an initial effect inducing GR upregulation and consequent improvement in feedback inhibition or, alternatively, on an initial facilitation of GR function followed by facilitated feedback inhibition and subse…”
BackgroundZobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705
The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death
Sapolsky, R. M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00971-9 · Cited by 699 · cited 1×
“, hippocampus CA3), although trophic effects have been observed at other sites, such as the hippocampal dentate gyrus, with lesser degrees of activation [14-17].”
BackgroundEffects of adverse experiences for brain structure and function
McEwen, B. S. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00964-1 · Cited by 639
Corticosteroids in relation to fear, anxiety and psychopathology
Korte, S. M. (2001) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(01)00002-1 · Cited by 607 · cited 1×
“In addition to these genomically mediated effects, corticosteroids may act directly with neuronal cell membranes and neuronal receptors and cause rapid changes in neural function through modulation of ion channels or second messenger systems, or through receptor mediated proteinprotein interactions [13].”
BackgroundDouble-blind treatment of major depression with dehydroepiandrosterone.
Wolkowitz, O. M., Reus, V. I., Keebler, A., Nelson, N., Friedland, M., Brizendine, L., & Roberts, E. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.646 · Cited by 411 · cited 1×
“Naturally-occurring compounds that serve to modulate glucocorticoid effects in vivo, such as dehydroepiandrosterone, may also exert antidepressant benefit, either as a sole treatment or combined with a proven antidepressant drug [71].”
BackgroundDeuschle, M., Schweiger, U., Weber, B., Gotthardt, U., Körner, A., Schmider, J., Standhardt, H., Lammers, C.-H., & Heuser, I. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3689 · Cited by 344
Treatment of major depression with steroid suppressive drugs
Pearson Murphy, B. E. (1991) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(91)90069-h · Cited by 67 · cited 1×
“Open-label 20 Aminoglutethimide, ketoconazole, metyrapone [45,46,61] [50]”
Yau, J. L. W., Noble, J., Hibberd, C., & Seckl, J. R. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01890-0 · Cited by 43
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Manji, H. K., Quiroz, J. A., Sporn, J., Payne, J. L., Denicoff, K., A. Gray, N., Zarate, C. A., & Charney, D. S. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00117-3 · Cited by 505
Chronic Stress-induced Hippocampal Vulnerability: The Glucocorticoid Vulnerability Hypothesis
Conrad, C. D. (2008) · Reviews in the Neurosciences · doi:10.1515/revneuro.2008.19.6.395 · Cited by 425
Neurobiology of chronic mild stress: parallels to major depression
Hill, M. N., Hellemans, K. G. C., Verma, P., Gorzalka, B. B., & Weinberg, J. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.07.001 · Cited by 420
Metadata
- Authors
- Reus, V. I., & Wolkowitz, O. M.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2001-10
- Volume
- 10
- Issue
- 10
- Pages
- 1789-1796
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2039126247
- Cited by
- 82
- References
- 13
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.